Supplementary material

Supplementary Table 1. Objective response rate in all patients.

Response	n=198 (%)
Best response	
Complete response	0 (0)
Partial response	21 (10.6)
Stable disease	94 (47.5)
Progressive disease	61 (30.8)
Not assessable	22 (11.2)
ORR	21 (10.6)

Abbreviations: ORR, objective response rate.

Supplementary Table 2. Objective response rate in the chemotherapy and endocrine therapy groups.

Response	Chemotherapy group n = 146 (%)	Endocrine therapy group n = 52 (%)
Best response		
Complete response	0 (0)	
Partial response	19 (13.0)	2 (3.8)
Stable disease	74 (50.7)	20 (38.5)
Progressive disease	37 (25.3)	24 (46.2)
Not assessable	16 (11.0)	6 (11.5)
ORR	19 (13.0)	2 (3.8)
p value	0.114	

Abbreviations: ORR, objective response rate.

Supplementary Table 3. Univariate and multivariate Cox regression analysis of factors associated with progression-free survival in the chemotherapy group.

Characteristic	HR (95%CI)	Univariate Cox analysis p-value	HR (95%CI)	Multivariate Cox analysis p-value
Age group (≥60 vs. <60)	0.793 (0.507-1.239)	0.308	0.741 (0.445-1.236)	0.251
Menopausal status (postmenopausal vs. premenopausal)	0.980 (0.628-1.530)	0.930	0.850 (0.515-1.403)	0.526
Disease-free interval (≤2y vs. > 2y)	0.974 (0.619-1.535)	0.911	0.780 (0.474-1.284)	0.329
Liver metastasis (no vs. yes)	1.017 (0.658-1.571)	0.941	1.000 (0.632-1.583)	0.999
Lung metastasis (no vs. yes)	1.447 (0.953-2.197)	0.083	1.270 (0.810-1.992)	0.298
Number of metastatic sites (< 2 vs. ≥ 2)	1.687 (0.953-2.983)	0.072	1.640 (0.859-3.133)	0.134
Lines of advanced systematic therapy of palbociclib (< 3 vs. ≥ 3)	1.346 (0.889-2.037)	0.161	1.229 (0.803-1.881)	0.342

Supplementary Table 4. Univariate and multivariate Cox regression analysis of factors associated with progression-free survival in the endocrine therapy group.

Characteristic	HR (95%CI)	Univariate Cox analysis p-value	HR (95%CI)	Multivariate Cox analysis p-value
Age group (≥60 vs. <60)	2.150 (0.991-4.666)	0.553	0.527 (0.218-1.272)	0.154
Menopausal status (postmenopausal vs. premenopausal)	1.197 (0.810-1.770)	0.367	0.939 (0.599-1.471)	0.784
Disease-free interval	0.786 (0.370-1.667)	0.530	0.846 (0.369-1.939)	0.693

(≤2y vs. > 2y)				
Liver metastasis (no vs. yes)	1.993 (0.986-4.028)	0.055	1.246 (0.492-3.158)	0.642
Lung metastasis (no vs. yes)	1.291 (0.643-2.590)	0.473	1.253 (0.591-2.655)	0.556
Number of metastatic sites (< 2 vs. ≥ 2)	1.826 (0.788-4.230)	0.160	1.438 (0.525-3.937)	0.480
Lines of advanced systematic therapy of palbociclib (< 3 vs. ≥ 3)	1.455 (0.700-3.024)	0.315	1.269 (0.579-2.783)	0.552